Cytogen Corp. (CYTO)
Merrill Lynch analyst Stuart Weisbrod lowered his long-term rating to "below average" from "neutral" following a review of the company's progress in its restructuring and focus on fewer development projects. He concluded that CYTO possibly needs more downsizing to stay viable.